Vascular dysfunction HFpEF, involving microvascular dysfunction and impaired nitric oxide (NO) signaling, responds to sGC stimulators (vericiguat, praliciguat), particularly in patients with pulmonary hypertension [36,37]. Here, SGCB is linked to pulmonary hypertension.